An arsenic trioxide nanoparticle prodrug (ATONP) potentiates a therapeutic effect on an aggressive hepatocellular carcinoma model via enhancement of intratumoral arsenic accumulation and disturbance of the tumor microenvironment

An arsenic trioxide nanoparticle prodrug has a therapeutic effect on a transgenic liver cancer model by disturbing the tumor micro-environment and increasing the delivery efficiency.